GlassScriptPhysician profile
Marcela Casas
NPI 1386311298
$7,081.59
in general payments reported to CMS, 2019-2025
39 companies · $3,074 in 2025
The $3,074 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.12 · 2022: $96.13 · 2023: $1,942 · 2024: $1,953 · 2025: $3,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,026 · Honoraria: $1,170 · Travel and Lodging: $763 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,026.13 |
| Honoraria | $1,170.00 |
| Travel and Lodging | $762.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $2,266.77 | 2023-2025 | Gocovri, Myobloc, Apokyn |
| Abbvie INC. | $636.63 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $616.98 | 2022-2025 | Ingrezza, Ongentys |
| Eisai INC. | $417.07 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $399.15 | 2023-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Teva Pharmaceuticals USA, INC. | $277.53 | 2023-2025 | Austedo Xr, Austedo Xr |
| Nevro Corp. | $274.66 | 2023-2024 | Senza, Vyrsa V1 |
| Merz Pharmaceuticals, LLC | $262.52 | 2023-2025 | Xeomin, Inbrija |
| Emd Serono, INC. | $184.75 | 2023-2024 | Mavenclad |
| Lilly USA, LLC | $168.19 | 2023-2025 | Amyvid, Kisunla |
| Ucb, INC. | $149.15 | 2023-2025 | Briviact, Zilbrysq |
| Lundbeck LLC | $148.28 | 2023-2025 | Vyepti |
| Neurelis, INC. | $138.66 | 2024-2025 | Valtoco |
| Kyowa Kirin, INC. | $114.18 | 2023-2024 | Nourianz |
| Argenx US, INC. | $106.47 | 2024 | Vyvgart Hytrulo |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $105.87 | 2023-2024 | Activa PC, Percept PC Brainsense |
| Supernus Pharmaceuticals, INC. | $105.75 | 2022-2024 | Qelbree |
| Biogen, INC. | $74.56 | 2021-2025 | Tysabri, Vumerity, Skyclarys |
| Tanabe Pharma America, INC. | $63.38 | 2023-2025 | Radicava |
| Acorda Therapeutics, INC | $58.62 | 2022-2024 | Inbrija, Ampyra |
| Harmony Biosciences LLC | $45.69 | 2024 | |
| Boston Scientific Corporation | $45.15 | 2024 | Wavewriter Alpha Prime 16, Lux-Dx Insertable Cardiac Monitor |
| Cala Health, INC. | $42.01 | 2025 | Cala Kiq |
| Takeda Pharmaceuticals U.S.A., INC. | $37.69 | 2025 | Hyqvia |
| Life Molecular Imaging LTD | $33.38 | 2025 | Neuraceq |
| Astrazeneca Pharmaceuticals LP | $32.41 | 2025 | Wainua |
| Amgen INC. | $30.42 | 2023 | Aimovig |
| Alexion Pharmaceuticals, INC. | $27.74 | 2024 | Ultomiris |
| Pfizer INC. | $25.96 | 2022 | |
| Csl Behring | $22.68 | 2025 | Hizentra |
| Upsher-Smith Laboratories LLC | $22.35 | 2023 | |
| Eli Lilly and Company | $21.40 | 2025 | Amyvid, Kisunla |
| Alnylam Pharmaceuticals INC. | $21.12 | 2025 | Onpattro |
| Otsuka America Pharmaceutical, INC. | $19.93 | 2024 | Rexulti |
| Biotronik Nro, INC. | $18.37 | 2025 | Prospera |
| Springworks Therapeutics, INC. | $17.79 | 2024 | |
| Genzyme Corporation | $16.80 | 2022 | |
| Grifols USA, LLC | $15.78 | 2025 | Gamunex-C |
| Avion Pharmaceuticals | $15.75 | 2023 | Dhivy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcela Casas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.